[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,211,200
  • Shares Outstanding, K 797,750
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,080 M
  • EBIT $ -869 M
  • EBITDA $ -869 M
  • 60-Month Beta -1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.89

Options Overview Details

View History
  • Implied Volatility 79.62% (-0.45%)
  • Historical Volatility 57.61%
  • IV Percentile 13%
  • IV Rank 17.59%
  • IV High 183.25% on 01/27/26
  • IV Low 57.51% on 01/21/26
  • Expected Move (DTE 1) 0.66 (5.04%)
  • Put/Call Vol Ratio 0.30
  • Today's Volume 770
  • Volume Avg (30-Day) 6,434
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 119,990
  • Open Int (30-Day) 111,388
  • Expected Range 12.50 to 13.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.28
  • Number of Estimates 3
  • High Estimate $-0.27
  • Low Estimate $-0.29
  • Prior Year $-0.31
  • Growth Rate Est. (year over year) +9.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.25 +7.76%
on 07/28/26
16.05 -17.76%
on 07/07/26
-1.37 (-9.40%)
since 06/30/26
3-Month
12.25 +7.76%
on 07/28/26
19.42 -32.01%
on 05/11/26
-8.26 (-38.49%)
since 04/30/26
52-Week
12.25 +7.76%
on 07/28/26
30.98 -57.39%
on 08/05/25
-13.46 (-50.49%)
since 07/30/25

Most Recent Stories

More News
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm

NEW YORK , July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT)...

SMMT : 13.23 (+3.36%)
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy ...

SMMT : 13.23 (+3.36%)
Summit Therapeutics: The Conference Call Scheduled After Tomorrow's Close

Barchart Research What to Expect from SMMT Earnings SMMT Generated July 22, 2026 Current Price $14.74 EPS Estimate $$-0.26 Consensus Rating Moderate Buy Average Move 7.42% Summit Therapeutics: The Conference...

SMMT : 13.23 (+3.36%)
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Data Expected to Be Generated by Mid-2027

SMMT : 13.23 (+3.36%)
RCUS : 28.00 (+5.86%)
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Data Expected to Be Generated by Mid-2027

SMMT : 13.23 (+3.36%)
RCUS : 28.00 (+5.86%)
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study

Western Patients Achieved OS HR of 0.76, Consistent with Asian Patients in this Global Phase III Study

SMMT : 13.23 (+3.36%)
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

Conference Call to Be Held at 4:30 p.m. EDT

SMMT : 13.23 (+3.36%)
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned...

SMMT : 13.23 (+3.36%)
Stocks Settle Sharply Lower on Escalating Middle East Tensions

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.98%. June...

ALK : 47.03 (+2.60%)
GOOGL : 332.19 (-1.34%)
MPC : 315.06 (+2.05%)
AAPL : 333.02 (-1.53%)
FDXF : 137.49 (-4.76%)
TSLA : 307.65 (+3.13%)
FANG : 197.65 (-0.74%)
STX : 842.35 (+10.19%)
WDC : 528.04 (+14.28%)
AMD : 488.94 (+13.82%)
SPY : 740.52 (+1.52%)
META : 532.90 (-9.00%)
Stocks Resume Decline as Chipmakers and AI Companies Fall

The S&P 500 Index ($SPX ) (SPY ) today is down -0.61%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures...

ALK : 47.03 (+2.60%)
MPC : 315.06 (+2.05%)
FDXF : 137.49 (-4.76%)
FANG : 197.65 (-0.74%)
WDC : 528.04 (+14.28%)
AMD : 488.94 (+13.82%)
SPY : 740.52 (+1.52%)
ILMN : 200.35 (+2.84%)
SMMT : 13.23 (+3.36%)
MU : 872.48 (+18.06%)
AAL : 15.36 (+3.50%)
QQQ : 682.58 (+3.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 14.20
2nd Resistance Point 13.72
1st Resistance Point 13.26
Last Price 13.23
1st Support Level 12.32
2nd Support Level 11.84
3rd Support Level 11.38

See More

52-Week High 30.98
Fibonacci 61.8% 23.83
Fibonacci 50% 21.61
Fibonacci 38.2% 19.40
Last Price 13.23
52-Week Low 12.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.